Phaco linked to posterior capsule rupture

Article

Phacoemulsification is linked to a higher rate of posterior capsule rupture in vitrectomized eyes, compared to combined vitrectomy and cataract surgery.

Phacoemulsification is linked to a higher rate of posterior capsule rupture in vitrectomized eyes, compared to combined vitrectomy and cataract surgery, claimed a paper in Retina.

Dr Jong Yeon Lee et al., Department of Ophthalmology, Gachon University Gil Hospital, Incheon, Korea, retrospectively reviewed the medical records of 54 patients who underwent cataract surgery in eyes that had previously been vitrectomized and 311 patients who experienced combined vitrectomy and cataract surgery. The main primary outcome measure was intraoperative complications during phacoemulsification and the secondary measures were preoperative and intraoperative cataract gradings.

It was discovered that the most common complication during phacoemulsification was posterior capsule rupture. The rate was higher in the sequential group than in the combined group, as was preoperative lens density.

Hard nucleus cataracts in vitrectomized eyes could have caused the higher rate of posterior capsule rupture in the sequential group.

Please click here for the abstract.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.